Skip to main content
OpenTrials
Completed

NCT Number: NCT07753395

Effects of New Zealand Blackcurrant on Athletic Performance and Physiological Stress in Simulated Volleyball Matches

Sixteen young, healthy, and physically active male college students were randomly assigned to receive either a placebo or NZBC supplement (300 mg/day) for seven days. Short-term NZBC supplementation enhanced athletic performance and effectively reversed inflammation and muscle damage induced by volleyball.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–30 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

China Medical University

Taichung, 404332, Taiwan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male subjects aged 18-30 who regularly practice volleyball and are willing to participate in the experiment.

Exclusion criteria

  • Smoking and alcohol consumption.
  • Patients with diabetes, heart disease, respiratory disease, coagulation disorders, hematomas, or other medical conditions.
  • Feeling unwell for other reasons during the study period.
  • Taking any health supplements or medications within the past two months. A medical history questionnaire was completed to exclude any medical conditions, such as recent muscle, bone, tendon, or ligament injuries, or those with a fear of blood draws.

Treatment and study plan

Placebo

Dietary Supplement

containing edible yellow No. 4, edible yellow No. 5, sucrose, silica, talc, oxidized starch, gelatin, magnesium stearate, and palm wax.

New Zealand blackcurrant (NZBC)

Dietary Supplement

New Zealand Blackcurrant 35% Anthocyanin Extract Powder, Capsule Shell (Hydroxypropyl Methylcellulose), Anti-caking Agent (Magnesium Stearate)

Primary outcomes

  1. Grip strength test

    Time frame: 28 days

    Handgrip strength of both hands was evaluated using a digital dynamometer (T.K.K. 5401 GRIP-D, Takei Scientific Instruments Co., Ltd., Niigata, Japan). During testing, participants maintained a standing position with the shoulder abducted at approximately 20°-30° without rotation, the forearm in a neutral position, and both the elbow and wrist in 0° extension. Participants were instructed to exert maximum effort gripping the handle for 5 seconds.

    Handgrip strength tests were conducted before and after the simulated volleyball matches, as well as during the rest interval between the first and second simulated matches. At each time point, two trials were performed for each hand with a 1-minute rest interval between trials, and the maximum value was recorded in kilograms (kg).

  2. Counter Movement Jump, CMJ

    Time frame: 28 days

    Vertical jump performance was analyzed using the My Jump 2 application. Participants started from an upright standing position with the body straight, then performed a rapid countermovement followed immediately by a maximal vertical jump. Each participant performed two trials with a 1-minute rest interval between trials, and the best trial was recorded for analysis.

  3. Agility T-test

    Time frame: 28 days

    Agility was evaluated using the T-test with the BlazePod light-based reaction training system (Play Coyotta Ltd., Tel Aviv, Israel), with time recorded in seconds (s).

    Course Layout:

    Point A served as the start line. Point B was placed 9.14 m directly in front of Point A. Points C and D were placed 4.57 m to the left and right of Point B, respectively. Reaction pods were placed at each point.

    Test Procedure:

    Timing began upon departure from Point A. Participants were required to touch each pod using their outside hand throughout the trial:

    Forward Sprint: Sprint forward from A to B and touch pod B. Left Shuffle: Side-shuffle left to C and touch pod C. Right Shuffle: Side-shuffle right past B to D and touch pod D. Return & Backpedal: Side-shuffle left back to B, touch pod B, then backpedal past A and touch pod A to complete the trial and stop timing.

  4. Standing spike

    Time frame: 28 days

    A designated landing area measuring 1.5 m x 1.5m was set up at a distance of 5 m from the net. The participant stood on a volleyball platform approximately 80 cm high and 1.5 m from the net. The participant was required to toss the ball to an appropriate height (approximately 1 m) and spike it into the designated area. Ball velocity was analyzed and recorded using the Kinovea motion analysis software (Kinovea, open-source video analysis software). Three trials were performed for each test, with a 30-second rest interval between trials.

  5. Clinical Biochemistry of muscle damage biomarkers and blood glucose

    Time frame: 28 days

    Blood samples were collected at four different time points (one and a half hours before the start of the volleyball special (B), immediately after the simulated volleyball game (E), after the experiment (24 hours), and after the experiment (48 hours). Changes in blood glucose levels were estimated using blood from the fingertips via an Accu-Chek® Guide blood glucose glucometer (Roche, Mannheim, Germany). Muscle damage biomarkers, including creatine kinase (CK), lactate dehydrogenase (LDH), and uric acid (UA), were measured in the serum. The CK (EC2.7.3.2), LDH (EC 1.1.1.27), and UA (C97792) concentrations were estimated using commercial analytical reagents (Beckman Coulter). An automated clinical chemistry analyzer was used to measure CK and LDH levels on a Beckman Coulter AU5800 (Beckman Coulter Inc., CA, USA).

  6. Clinical Biochemistry of the inflammatory response

    Time frame: 28 days

    Blood samples were collected at four different time points (one and a half hours before the start of the volleyball special (B), immediately after the simulated volleyball game (E), after the experiment (24 hours), and after the experiment (48 hours). According to the manufacturer's instructions, the pro-inflammatory cytokine TNF-α was analyzed with a commercial ELISA kit (BioLegend, San Diego, CA). An enzyme immunoassay read The absorbance at 450 nm within 15 minutes (Tecan GENios, A-5082, Austria). Concentrations of C-reactive protein (CRP) were measured using a human ELISA kit (E-80CRP, Immunology Consultants Laboratory, Inc., Newberg, OR, USA). The sample absorbance was read at 450 nm within 30 min.

Secondary outcomes

  1. Superoxide Dismutase (SOD) Activity

    Time frame: 28 days

    biomarker used to evaluate total antioxidant capacity. Serum SOD activity is measured using a commercial colorimetric assay kit and read with an ELISA plate reader.Unit of Measure: Units per milliliter (U/mL).

  2. Rating of Perceived Exertion, RPE

    Time frame: 28 days

    This experiment used a version developed by Swedish psychologist Gunnar Borg, using a scale ranging from 6 to 20. During breaks and after each round of a simulated volleyball match, participants were asked to clearly indicate their RPE (Rate of Perceived Effort) on a paper-based scale. The corresponding level was used to determine the participant's current level of exertion and to record this number.

  3. Visual analogue scale, VAS

    Time frame: At the end of the simulated volleyball match, and 12, 24, 36, and 48 hours after the match, please clearly indicate the corresponding facial expression and record it by number.

    The VAS is a pain scale developed by Donna Wong and Connie Baker. Six cartoon faces are drawn on a piece of paper. From left to right, they are: no pain (0), a little pain (2), some pain (4), pain (6), very painful (8), and severe pain (10). Scales from 0 to 10 are marked below the faces, as shown in Figure 6. This scale will be used at three time points: immediately after the simulated volleyball match, and 12, 24, 36, and 48 hours after the match. Please clearly indicate the corresponding face and record it according to the number.

Sponsors and collaborators

Lead sponsor

China Medical University Hospital

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Aug 7, 2026
Registry last updated
Aug 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.